The median CRP levels ranged from 0.84 mg/dL (week 0) to 0.55 mg/dL (week 12) ( P = 0.359, Table 3 ). Among the inflammatory markers tested, MTX treatment had a highly significant impact on two chemokines, that possess both chemotactic and angio-modulatory properties.
← all excerpts
Low-dose methotrexate in sickle-cell disease: a pilot study with rationale borrowed from rheumatoid arthritis.
1
—
—